Modality
ADC
MOA
EZH2i
Target
CDK4/6
Pathway
Proteasome
CML
Development Pipeline
Preclinical
Mar 2023
→ Aug 2031
PreclinicalCurrent
NCT07372234
1,290 pts·CML
2024-11→2030-10·Recruiting
NCT06138207
1,020 pts·CML
2023-03→2031-08·Active
2,310 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-10-274.6y awayInterim· CML
2031-08-125.4y awayInterim· CML
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Active
Preclinical
Recruit…
Catalysts
Interim
2030-10-27 · 4.6y away
CML
Interim
2031-08-12 · 5.4y away
CML
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07372234 | Preclinical | CML | Recruiting | 1290 | 6MWD |
| NCT06138207 | Preclinical | CML | Active | 1020 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |